Status:
ENROLLING_BY_INVITATION
Oral Melatonin Versus Oral Tranexamic Acid in the Management of Melasma
Lead Sponsor:
Hina Malik
Conditions:
Melasma (Facial Melasma)
Eligibility:
All Genders
18-50 years
Phase:
PHASE2
Brief Summary
This study will compare the efficacy of oral melatonin and oral tranexamic acid in treating melasma, with the aim of determining whether melatonin is more effective than tranexamic acid, as measured b...
Detailed Description
This study will compare the efficacy of oral melatonin and oral tranexamic acid in treating melasma.Literature suggests melatonin may be more effective due to its antioxidant, anti-inflammatory, and a...
Eligibility Criteria
Inclusion
- Adult patients aged 18-50 years diagnosed with melasma.
- Both genders.
Exclusion
- Patients with contraindications to melatonin, including pregnancy, breastfeeding, autoimmune disorders, bleeding disorders, and diabetes, or contraindications to tranexamic acid, including thromboembolic events, history of thrombosis, renal impairment, and pregnancy or breastfeeding.
- Patients with a history of hypersensitivity to any of the medications.
- Patients already taking treatment of melasma
Key Trial Info
Start Date :
June 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 28 2025
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT07169383
Start Date
June 28 2025
End Date
December 28 2025
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PAEC General Hospital Islamabad Pakistan
Islamabad, Punjab Province, Pakistan, 44000